About us

Theranyx is a French biotech company founded in 2010 on a unique technology platform that has proved instrumental in the development of novel therapeutic solutions for the treatment of cancer. 

 

Our mission

We are in a position to propose an extensive collection of membrane receptors and related products and services. Our product line will not be limited to membrane preparations and stable cell lines, but also purified receptors and reconstituted vesicles, which constitute an exclusive alternative for the market today. We have demonstrated rapid discovery of functional antibody fragments using purified active receptors (patent pending). Functional antibody fragments can significantly improve the development of molecules modulating specifically the activity of ion channels and the discovery of novel regulation mechanisms. Our goal is to systematically screen for functional antibodies targeting purified receptors either using our own antibody development platform or through strategic partnerships.